How Targeted Therapies Are Reshaping Treatment for Platinum-Resistant Ovarian Cancer

Platinum-resistant ovarian cancer remains one of the most challenging settings in oncology, with limited treatment options and historically poor outcomes for many patients. In this episode of Unscripted, the AMCP Podcast, guest host Abby Kim, PharmD, BCOP, Senior Director of Clinical Strategy and Oncology Specialty Solutions at Prime Therapeutics, sits down with Kathleen Moore, MD, Deputy Director of the Fred & Pamela Buffett Cancer Center and Professor of Obstetrics and Gynecology at Nebraska Medicine, to discuss the evolving treatment landscape for recurrent ovarian cancer and the growing role of biomarker-driven care. Dr. Moore explores the history and challenges of treating platinum-resistant disease, reviews the clinical evidence behind ELAHERE® (mirvetuximab soravtansine-gynx), examines the importance of folate receptor alpha testing, and shares insights on treatment sequencing, patient-reported outcomes, safety and tolerability considerations, and emerging therapies that may further expand options for patients and inform decision-making across managed care. Sponsored by Abbvie, Inc.

Unscripted offers valuable updates for listeners and connects sponsors with health care professionals, payers, policymakers, regulators, and industry leaders. Sponsors benefit from a platform that connects them with a wide network of health care professionals, payers, and industry leaders. View podcast partner and advertising options, and view other Corporate Opportunities. 

View all podcasts: AMCP.org/podcast